Evidence map›Paper›PMID 39615656›Full record

ArticleInternational journal of radiation oncology, biology, physics2025

Consolidation Regimen and Cerebral Atrophy in Patients With Primary Central Nervous System Lymphoma.

Kathryn R Tringale, Christian Grommes, Burcin A Ucpinar, Anne S Reiner, Joachim Yahalom, Gustav Y Cederquist, Lauren R Schaff, Vaios Hatzoglou, Robert J Young, Mousa Payinkay and 4 more

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kathryn R TringaleDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: katringale@health.ucsd.edu.
Christian GrommesDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.
Burcin A UcpinarDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Anne S ReinerDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Joachim YahalomDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Gustav Y CederquistDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Lauren R SchaffDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.
Vaios HatzoglouDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert J YoungDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Mousa PayinkayDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Grace BartlettDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael ScordoAdult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.
Brandon S ImberDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Javin ScheffleinDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeIn primary central nervous system lymphoma (PCNSL), the extent to which post-methotrexate consolidation contributes to neurotoxicity is unclear. Concerns for neurotoxicity from standard dose whole-brain radiation therapy (WBRT) have led to declining use. Cerebral atrophy is an established surrogate for neurotoxicity; however, the relative extent to which modern consolidation (ie, reduced-dose [RD-]WBRT ≤24 Gy, autologous hematopoietic cell transplant) contributes to cerebral atrophy is unclear. METHODS AND MATERIALS: Patients with PCNSL from 2000-2020 who achieved a complete response to consolidation following methotrexate-based induction were included. Inclusion criteria were preconsolidation magnetic resonance imaging (baseline) and ≥1 magnetic resonance imaging showing sustained remission at 1, 3, 5, or 10 years. An expert neuroradiologist longitudinally measured parenchymal volume loss via ventricular volumetric change. Linear mixed-effects models were performed to estimate absolute and annual volumetric change rates.

resultsOf 139 patients (median follow-up, 4.5 years), most were Memorial Sloan Kettering Cancer Center (MSK) recursive partitioning analysis (RPA) class 2 (age ≤50 years, Karnofsky performance score (KPS) ≥70). Consolidation therapies included nonmyeloablative chemotherapy (n = 57; 41%), high-dose myeloablative chemotherapy with autologous hematopoietic cell transplant (n = 50; 36%), and RD-WBRT (n = 28; 20%). A higher MSK RPA class was associated with greater baseline ventricular volume (P < .001). Overall adjusted annual ventricular volume change rates were greater than those published in healthy controls (4.3% vs 1.8%) and generally increased by age/decade at diagnosis: 40 to 49-year-olds 1.8% (95% CI, -1.4% to 5.0%), 50 to 59-year-olds 3.1% (95% CI, 0.7%-5.5%), 60 to 69-year-olds 4.8% (95% CI, 2.4%-7.3%), 70 to 79-year-olds 7.2% (95% CI, 4.3%-10.2%), and 80 to 89-year-olds 4.2% (95% CI, -1.1% to 9.6%). There were no significant associations between consolidation strategy and ventricular volume change rates accounting for age, KPS, gender, baseline ventricular volume, or interaction between age and consolidation.

conclusionsThese findings demonstrate accelerated cerebral atrophy in PCNSL after consolidation compared with healthy adults. However, atrophy did not differ by consolidation strategy. These long-term results suggest acceptable neurotoxicity following RD-WBRT.

Indexed as

BrainCentral Nervous System NeoplasmsConsolidation ChemotherapyCranial IrradiationLymphomaAdultAgedAtrophyFemaleHematopoietic Stem Cell TransplantationHumansMagnetic Resonance ImagingMaleMethotrexateMiddle AgedRetrospective StudiesMethotrexate

Identifiers

PMID39615656
PMCPMC12939629

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.